0001193125-26-104150
SEC filingErasca, Inc. (ERAS), a clinical-stage precision oncology company, reported a net loss of $124.5M for FY 2025 ending December 31, 2025, improved from $161.7M in FY 2024, driven by reduced operating expenses. Total operating expenses fell 22% YoY to $140.9M, with R&D down 20% to $92.9M due to lower clinical trial and preclinical costs following pipeline prioritization, in-process R&D decreased to $9.5M from $22.5M, and G&A declined 8% to $38.6M. No revenue was generated as no products are approved. Cash position strengthened to $341.8M in cash equivalents and marketable securities from prior periods, bolstered by $242.7M net proceeds from January 2026 offering (post $150M Joyo payment). Balance sheet shows $396.2M total assets, $325.2M stockholders' equity, and $71.0M liabilities. Operating cash burn improved to $95.5M from $109.4M. With runway into H2 2028, focus remains on RAS/MAPK programs: ERAS-0015 (Phase 1 data H1 2026) and ERAS-4001 (H2 2026), amid high R&D intensity signaling continued investment in clinical advancement.
Erasca reported FY2025 net loss of $124.5M, a 23% improvement from $161.7M in FY2024, primarily due to 22% lower total operating expenses at $140.9M versus $179.6M prior year. Loss from operations narrowed to $140.9M from $179.6M. No revenue generated as pre-commercial biotech. Other income net $16.4M (down from $17.9M) offset losses. Balance sheet strengthened with $396.2M total assets (up from prior implied), $286.2M current assets including $73.8M cash equivalents and $202.3M short-term marketable securities. Stockholders' equity $325.2M, accumulated deficit $892.2M. Strategic pipeline focus post-reprioritization reduced costs while advancing key RAS programs.
No revenue reported in FY2025 or FY2024, consistent with clinical-stage status. Company derives no product sales; all focus on R&D for RAS/MAPK oncology candidates like ERAS-0015 and ERAS-4001. Future revenue contingent on regulatory approvals, expected years away.
Pre-revenue, gross margins not applicable. Operating loss margin effectively 100% of expenses at $140.9M. R&D comprised 66% of opex ($92.9M, down 20% YoY from clinical wind-downs), G&A 27% ($38.6M, down 8%), in-process R&D 7% ($9.5M). Cost reductions from pipeline reprioritization (e.g., naporafenib termination) and facility impairments in 2024. Stock-based comp $24.9M supported non-cash profitability drag.
Operating cash use $95.5M (improved from $109.4M). Investing provided $100.4M net (maturities $261.0M exceeded purchases $151.0M). Financing $1.1M (ESPP/options). Ending cash/equiv/restricted $93.5M. Total liquidity $341.8M supports operations to H2 2028 post-2026 raise ($242.7M net) less Joyo $150M. Debt-free; leases $71.0M liabilities. Shares outstanding 284.2M.
Management guides cash sufficient into H2 2028 barring changes. Priorities: ERAS-0015 Phase 1 readout H1 2026, expansion/combos H2 2026; ERAS-4001 readout H2 2026. Risks include clinical delays, milestone payments, funding needs. No revenue guidance; continued losses expected until approvals.